Bard Vascular Systems
Division of Becton Dickinson & Co.
Latest From Bard Vascular Systems
A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. This week, the US FDA approved Boston Scientific’s Vici Venous iliac vein stent system and SentreHEART announced it has received a CE mark for the 50mm version of the Lariat-RS system for left atrial appendage exclusion in patients with atrial fibrillation.
The US FDA approval of Boston Scientific's Vici venous stent is based on VIRTUS trial results which met the prespecified performance goal for primary patency after one year.
Global Device Approvals, Weekly Snapshot: FDA Approves Bard’s Venovo Stent; Abbott’s MitraClip Gets Indication-Expansion; Boston Scientific’s Watchman FLX Earns CE Mark
A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. This week, FDA approved Bard’s Venovo venous stent system for symptomatic iliofemoral venous outflow obstruction, FDA added functional mitral regurgitation to the approved labeling for Abbott’s market-leading MitraClip, and Watchman FLX, Boston Scientific’s next-generation left-atrial appendage closer earned a CE Mark in Europe.
The Society for Cardiovascular Angiography and Interventions’ Vascular Disease Council says the recent meta-analysis finding a higher long-term mortality risk with paclitaxel-eluting peripheral devices can only be viewed as hypothesis-generating. The long-term risks of these devices should be investigated with patient-level data, SCAI argues. Several clinical data presentations at the recent LINC meeting in Leipzig showed comparable mortality rates with paclitaxel-eluting devices as comparable non-drug-eluting devices.
- Medical Devices
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Becton Dickinson & Co.
- Senior Management
- Donald Z Maciorowski, Materials Manager
- Contact Info
Bard Vascular Systems
Phone: (978) 373-1000
25 Computer Dr.
Haverhill, MA 01832
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.